论文部分内容阅读
肠球菌(ｅｎｔｅｒｏｃｏｃｃｕｓｆａｅｃｉｕｍ)和ＭＲＳＡ(甲氧西林抗金葡球菌)感染是住院或无免疫应答患者的一个特殊问题。这些微生物常对多种抗生素有抗药性,因此,对这些感染患者没有多少治疗选择。Ｚｙｖｏｘ(ｌｉｎｅｚｏｌｉｄ)是ＰＵ公司开发并于今年4月18日获ＦＤＡ
Enterococcus faecium and MRSA (methicillin-resistant Staphylococcus aureus) infections are a particular problem in hospitalized or non-immune patients. These microbes are often resistant to multiple antibiotics, so there are not many treatment options for these infected patients. Zyvox (linezolid) was developed by PU and received FDA approval on April 18 this year